Article

Chinese version of the M. D. Anderson Symptom Inventory: validation and application of symptom measurement in cancer patients.

Division of Internal Medicine, Department of Symptom Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer (Impact Factor: 4.9). 11/2004; 101(8):1890-901. DOI: 10.1002/cncr.20448
Source: PubMed

ABSTRACT Symptom management is an essential component of cancer treatment for patients of every culture and nationality. Symptom assessment depends on subjective reporting, mandating linguistically equivalent versions of symptom assessment scales. Because disease-related and treatment-related symptoms most often occur in clusters, there is a global need for a standardized multiple-symptom assessment tool.
The authors sought to validate the Chinese version of the M. D. Anderson Symptom Inventory (MDASI-C) by enrolling patients who had received various diagnoses of and different types of treatment for cancer (n = 249) in a cross-sectional symptom study conducted at an urban cancer center in China.
Factor analysis identified 2 underlying constructs, general symptoms and gastrointestinal symptoms, which had Cronbach alpha coefficients of 0.86 and 0.84, respectively. These results were consistent with English- and Japanese-language MDASI validation studies. Known-group validity was supported by the MDASI-C's ability to detect significant differences in symptom and interference levels according to Eastern Cooperative Oncology Group performance status (ECOG PS; P < 0.001) and chemotherapy status (P < 0.05). Fifty-five percent of the study cohort had > or = 1 symptom that was considered severe (score > or = 7 on a 0-10 scale). ECOG PS was strongly associated with symptom burden (total interference score: R(2) = 0.26; P < 0.001). Fatigue, sadness, drowsiness, and lack of appetite accounted for most of the variability in the total interference score (R(2) = 0.49; P < 0.05).
The authors demonstrated that the MDASI-C is a valid, reliable, and concise tool for measuring symptom severity and interference with functioning in Chinese cancer patients.

0 Bookmarks
 · 
87 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Colorectal cancer is a major public health problem. There is growing support for colorectal cancer survivors who are experiencing problems after cancer treatment to engage in self-management programs to reduce symptom distress. However, there is inconclusive evidence as to the effectiveness of such program especially in Asian region. Objectives This study tested the effects of a six-month nurse-led self-efficacy-enhancing intervention for patients with colorectal cancer, compared with routine care over a six-month follow up. Design A randomized controlled trial with repeated measures, two-group design. Setting Three teaching hospitals in Guangzhou, China. Participants: One hundred and fifty-two Chinese adult patients with a diagnosis of colorectal cancer were recruited. The intervention group (n = 76) received self-efficacy-enhancing intervention and the control group (n = 76) received standard care. Method The participants were randomized into either intervention or control group after baseline measures. The outcomes of the study (self-efficacy, symptom distress, anxiety, depression and quality of life) were compared at baseline, three and six months after the intervention. Results Sixty-eight participants in the intervention group and 53 in the control group completed the study. Their mean age was 53 (SD = 11.3). Repeated measure MANOVA found that the patients in the intervention group had significant improvement in their self-efficacy (F = 7.26, p = 0.003) and a reduction of symptom severity (F = 5.30, p = 0.01), symptom interference (F = 4.06, p = 0.025), anxiety (F = 6.04, p = 0.006) and depression (F = 6.96, p = 0.003) at three and six months, compared with the control group. However, no statistically significant main effect was observed in quality of life perception between the two groups. Conclusions The nurse-led self-efficacy enhancing intervention was effective in promoting self-efficacy and psychological well-being in patients with colorectal cancer, compared with standard care. The intervention can be incorporated into routine care. Future empirical work is required to determine the longer term effects of the intervention.
    International journal of nursing studies 01/2013; · 1.91 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Depression is a significant concern in outpatient oncology care, yet clinicians face practical challenges in accurately and efficiently screening patients for it. This study investigated whether a single item or multiple items from an existing multisymptom scale, the MD Anderson Symptom Inventory (MDASI), might serve as effective initial screens for depressed mood. Data were collected from two cohorts of patients. Cohort 1 comprised 187 patients with non-small-cell lung cancer who completed the Beck Depression Inventory II; cohort 2 comprised 281 patients with renal cell carcinoma who completed the Center for Epidemiologic Studies Depression Scale. All patients completed the MDASI. Single-item and multiple-item MDASI solutions were identified using cohort 1 and validated in cohort 2. Sensitivity and specificity of the solutions were assessed through binary linear regression; cut points were identified using receiver operating characteristic analysis. The MDASI single item "sadness" was the best solution identified in cohort 1 for screening for depressed mood relative to other affective items (distress, enjoyment of life, mood). At a cut point ≥ 4 (0 to 10 scale), the "sadness" item exhibited a clinically acceptable specificity of 81.5%, sensitivity of 72.0%, a negative predictive value of 95.0%, and a positive predictive value of 37.5%. This solution was successfully validated in cohort 2. The MDASI "sadness" item has modest sensitivity and high negative predictive value and can serve as a useful initial screen for depressed mood. This approach may improve the efficiency and acceptability of depression screening for both clinicians and patients.
    Journal of Oncology Practice 11/2013;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Patients with cancer who are receiving chemotherapy often experience chemotherapy-induced anemia (CIA), which is associated with symptoms that reduce quality of life. The M. D. Anderson Symptom Inventory (MDASI) is a brief, self-rating assessment scale that measures the severity of core symptoms and symptom interference with function. The current study used the MDASI to prospectively assess the correlation between hemoglobin and self-perceived cancer-related symptoms in a large patient population with CIA who were receiving darbepoetin-alpha at a dose of 200 mug every 2 weeks. Eligible patients enrolled in this multicenter, open-label study were age > or =18 years, had a nonmyeloid malignancy, were receiving multicycle chemotherapy, and were anemic (hemoglobin < or = 11 g/dL). Hemoglobin was measured every 2 weeks; the MDASI was administered weekly. For hemoglobin-based endpoints, patients were stratified by baseline hemoglobin (< 10 g/dL or > or =10 g/dL). Of 2422 enrolled patients, 2401 received > or =1 dose of darbepoetin-alpha. Eighty percent of patients (95% confidence limit, 78-82 patients) achieved target hemoglobin levels (> or =11 g/dL) during the study. Patients with a baseline hemoglobin < 10 g/dL had a greater increase in hemoglobin, took longer to achieve the target hemoglobin, and received more red blood cell transfusions than patients with a baseline hemoglobin > or =10 g/dL. The percentage of patients with moderate to severe MDASI scores (> or =5 points) for fatigue, distress, loss of appetite, disturbed sleep, and interference with function was reduced during the study. Improvement in symptom burden was associated with an increase in hemoglobin concentration. Treatment with darbepoetin-alpha at a dose of 200 mug every 2 weeks is associated with improvement in symptom burden as measured by the MDASI, a simple tool that may improve symptom management for cancer patients with CIA.
    Cancer 01/2007; 110(7):1629-1640. · 4.90 Impact Factor

Preview

Download
0 Downloads